Otic formulations, methods and devices

1. A formulation for treating ear infection, comprising:

a) active ingredients for treating fungal and bacterial infections, comprising:

i) a fluoroquinolone;

ii) a triazole antifungal;

iii) a thiocarbamate antifungal;

iv) a corticosteroid; and

v) a polyene antifungal, and

b) a carrier;

wherein said formulation is capable of delivery to the ear canal of a mammal in a flowable fluid form, and

wherein said carrier includes at least one thickener so that upon introduction into the ear canal the formulation remains in the ear canal for at least 3 days releasing said active ingredients.

2. The formulation of claim 1 , wherein said carrier comprises: about 10-90% of said thickener.

3. The formulation of claim 1 , wherein said carrier comprises 10% to 90% of said thickener; and 30% to 70% of mineral oil.

4. The formulation of claim 1 , wherein said carrier comprises 75-90% mineral oil and 10% to 25% of wax.

5. The formulation of claim 1 , wherein said carrier comprises 82% of said mineral oil and 18% of paraffin.

6. The formulation of claim 1 , wherein said formulation comprises 0.01% to 1% by weight of said fluoroquinolone that is selected from the group consisting of: ciprofloxacin, ofloxacin, levofloxacin, norfloxacin, gatifloxacin, gemifoxacin, moxifloxacin and combinations thereof.

7. The formulation of claim 6 , wherein said fluoroquinolone is ciprofloxacin, ofloxacin or the combination thereof.

8. The formulation of claim 1 , wherein said formulation comprises 0.1% to 2% by weight of said triazole antifungal that is selected from the group consisting of: clotrimazole, ketoconazole, itraconazole, fluconazole, miconazole, econazole, butoconazole, oxiconazole, sulconazole, terconazole, and the combination thereof.

9. The formulation of claim 8 , wherein said triazole antifungal is clotrimazole, ketoconazole, itraconazole, miconazole and the combination thereof.

10. The formulation of claim 1 , wherein said formulation comprises 0.1% to 2% by weight of said thiocarbamate antifungal that is tolnaftate.

11. The formulation of claim 1 , wherein said formulation comprises 0.01% to 2.5% by weight of said corticosteroid that is selected from the group consisting of: amcinonide, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clocortolone pivalate, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate, fluocinonide, fluocinolone acetonide, flurandrenolide, fluticasone propionate, halcinonide, halobetasol propionate, hydrocortisone, hydrocortisone butyrate, hydrocortisone valerate, mometasonefuroate, prednisolone acetate, triamcinolone acetonide, and the combination thereof.

12. The formulation of claim 11 , wherein said corticosteroid is dexamethasone, hydrocortisone, triamcinolone acetonide or the combination thereof.

13. The formulation of claim 1 , wherein said formulation comprises 50,000 to 200,000 unit/ml of said polyene antifungal, wherein said polyene antifungal is nystatin.

14. The formulation of claim 1 , wherein said formulation has a viscosity of about 62,000 cPs at 37° C.

15. A formulation for treating ear infection, comprising:

a) active ingredients for treating fungal and bacterial infection comprising:

i) about 0.3% by weight of ciprofloxacin, ofloxacin, or the combination thereof;

ii) about 1% by weight of a clotrimazole, itraconazole, or the combination thereof;

iii) about 1% by weight of a tolnaftate;

iv) about 0.1% by weight of a dexamethasone; and

v) about 100,000 unit/ml of a nystatin;

b) about 10-25% of wax; and

c) about 75-90% of mineral oil;

d) wherein after applying to the ear canal of a mammal having said ear infection, said formulation remains in the ear canal and has a viscosity of about 62,000 cPs at 37° C.; and

e) wherein upon introduction into the ear canal said formulation remains in the ear canal releasing said active ingredients for 2-7 days, and thereafter is not found in said ear, and

f) wherein said formulation is for single treatment and has a cure rate of at least 95%.

16. A formulation for treating ear infection, comprising

a) one or more antifungal agents;

b) one or more anti-bacterial agents;

c) one or more anti-inflammatory agents; and

d) a carrier having 40,000-80,000 cPs at 37° C., wherein said carrier retains said active ingredients in an ear for 2-7 days and then egresses or is absorbed,

wherein said formulation is for single treatment and has a cure rate of at least 95%.

17. An otic formulation, comprising ciprofloxacin, dexamethasone and clotrimazole in an aurally acceptable carrier, said carrier having 40,000-80,000 cPs at 37° C., wherein said carrier retains said active ingredients in an ear for 2-7 days and then egresses or is absorbed, wherein said formulation is for single treatment and has a cure rate of at least 95%.

18. An otic formulation, selected from:

0.01% fluoroquinolone, 0.1% triazole antifungal, 0.1% thiocarbamate,

0.01% corticosteroid, and 50,000 unit/ml of a polyene antifungal plus thickener and mineral oil;

1% fluoroquinolone, 2% triazole antifungal, 2% thiocarbamate, 1% by weight of a corticosteroid, and 200,000 unit/ml of a polyene antifungal in thickener, and mineral oil;

0.3% ciprofloxacin, 1% clotrimazole, 1% tolnaftate, 0.1% dexamethasone; and 100,000 unit/ml of a nystatin in an otic carrier that is 10-25% wax, and 75-90% of mineral oil;

0.3% ciprofloxacin, 1% ofloxacin, 1% itraconazole, 1% tolnaftate 0.1% dexamethasone, and 100,000 unit/ml of a nystatin in 10-25% wax and 75-90% mineral oil;

0.3% ciprofloxacin, 1% ofloxacin, 1% itraconazole, 1% tolnaftate, 0.1% dexamethasone, and 100,000 unit/ml of nystatin in 55-60% PCCA Plasticized™ and 40-45% mineral oil;

0.3% ciprofloxacin, 1% ofloxacin, 1% clotrimazole, 1% tolnaftate 0.1% dexamethasone, and 100,000 unit/ml of a nystatin in 55-60% PCCA Plasticized™ and 40-45% mineral oil;

0.3% ciprofloxacin ofloxacin or the combination thereof, 1% by weight of a clotrimazole, itraconazole, or the combination thereof; 1% by weight of a tolnaftate; 0.1% by weight of a dexamethasone; and 100,000 unit/ml of a nystatin in an otic carrier that is 10-25% of wax; and 75-90% of mineral oil;

0.3% ciprofloxacin, 100,000 u/ml Nystatin, 1% Itraconazole, 0.1% Dexamethasone and 1% Tolnaftate in 18% candela wax and 82% mineral oil;

0.3% ciprofloxacin; 100,000 u/ml Nystatin, 1% clotrimazole, 0.1% Dexamethasone, 1% Tolnaftate (1%) in 80% mineral oil and 20% bees wax;

0.3% ciprofloxacin; 100,000 u/ml Nystatin, 1% clotrimazole, 0.1% Dexamethasone, 1% Tolnaftate in 82% mineral oil and 18% paraffin;

0.3% ciprofloxacin; 100,000 u/ml Nystatin, 1% clotrimazole, 0.1% Dexamethasone, 1% Tolnaftate in mineral oil and wax;

0.3% ciprofloxacin; 1% clotrimazole, 0.1% Dexamethasone in 82% mineral oil and 18% paraffin;

0.5% ciprofloxacin; 2% clotrimazole, 0.2% Dexamethasone in 82% mineral oil and 18% paraffin;

0.6% ciprofloxacin; 2% clotrimazole, 0.2% Dexamethasone in 82% mineral oil and 18% paraffin;

0.3% ciprofloxacin, 100,000 u/ml Nystatin, 0.1% dexamethasone;

0.3% ciprofloxacin, 1% voriconazole, 0.1% dexamethasone;

0.3% ciprofloxacin, 1% amphotericin B, 0.1% dexamethasone;

0.3% levofloxacin, 1% amphotericin B, 0.1% dexamethasone;

0.3% levofloxacin, 1% voriconazole, 0.1% dexamethasone;

0.3% ciprofloxacin, 1% ketoconazole, 0.1% dexamethasone; and

0.3% Ciprofloxacin; 1% clotrimazole, 0.1% hydrocortisone.

19. A method for treating ear infection, comprising applying a single dose of the formulation as in one of claim 1 - 18 into the ear canal of a mammal with an ear infection.

20. A therapeutic kit, comprising an injection unit comprising a storage compartment fluidly coupled to a delivery component, and a therapeutic formulation of claim 1 stored within said storage compartment, and wherein said delivery component comprises disposable needles having a 5-15 degree bend and a rounded tip.